Outstanding Preliminary Results of A Clinical Trial Treating Moderate-To-Severe Covid-19 Patients, Conducted By Amorphical, An Israeli Biotechnology Company


Amorphical, an Israeli biotech company developing Amorphous Calcium Carbonate (ACC) has announced results of a phase II clinical trial.

Amorphical’s Novel COVID-19 Amorphous Calcium Carbonate (ACC) Treatment Significantly Reduces the Risk of ICU Admission and Mortality in Interim Analysis of a Phase II Study Involving Patients Hospitalized with Moderate-to-Severe COVID-19. (NIH Clinical Trial Registration No. NCT04900337)

Published by Amorphical, Ness Ziyona, Israel | January 06, 2022 



Read more on the Jerusalem Post (published December 22, 2021):




Leave a comment

All blog comments are checked prior to publishing
You have successfully subscribed!
This email has been registered